Bruton agammaglobulinemia tyrosine kinase

Overview

Bruton agammaglobulinemia tyrosine kinase (BTK) is a non-receptor tyrosine kinase that plays an essential and non-redundant role in B-cell development, maturation, and signaling. It is a member of the Tec family of kinases and is encoded by the BTK gene located on the X chromosome. BTK was originally identified as the gene mutated in X-linked agammaglobulinemia (XLA), a primary immunodeficiency characterized by the near-complete absence of circulating B cells and immunoglobulins. In physiological B-cell biology, BTK functions as a pivotal component of the B-cell receptor (BCR) signaling cascade, transmitting activation signals downstream through phospholipase C gamma 2 (PLCG2) and connecting to pathways including the PI3K/Akt signaling pathway, NF-κB, and MAPK. Beyond its canonical role in lymphocytes, BTK is expressed in myeloid lineage cells including neutrophils and macrophages, where it participates in innate immune receptor signaling.

Given its central position in BCR-mediated survival and proliferation signals, BTK has emerged as one of the most validated pharmacological targets in hematological oncology. Small-molecule inhibitors of BTK — spanning covalent, irreversible agents (such as ibrutinib) and next-generation non-covalent inhibitors — have transformed the treatment landscape for B-cell malignancies, particularly chronic lymphocytic leukemia (CLL). More recently, BTK has attracted attention in inflammatory and autoimmune disorders, as well as in exploratory investigations in neurological conditions, reflecting the breadth of its signaling roles across hematopoietic and immune cell types.

Focus of Latest Publications

Recent publications demonstrate that Bruton tyrosine kinase (BTK) remains a central therapeutic target across multiple disease contexts. BTK functions as a key signaling molecule in B cells, myeloid cells, and platelets, with distinct roles in cell activation, antibody production, and inflammatory pathways. The breadth of current research reflects both the maturation of BTK-targeting therapies and the ongoing challenge of overcoming acquired resistance in treated populations.

In hematologic malignancies—particularly chronic lymphocytic leukemia, small lymphocytic lymphoma, and diffuse large B-cell lymphoma—BTK inhibitors and a new class of BTK degraders are under active investigation. Phase 2 and Phase 1 trials demonstrate activity of next-generation non-covalent inhibitors such as docirbrutinib and rocbrutinib in heavily pretreated populations with prior BTK exposure, alongside rapid and deep responses from BTK degraders including bexobrutideg and BGB-16673. In primary central nervous system lymphoma, the highly selective BTK inhibitor orelabrutinib crosses the blood-brain barrier effectively and shows superior outcomes when combined with methotrexate in patients with MyD88L265P mutations, providing a molecular rationale for frontline incorporation of BTK-directed therapy in this aggressive setting. Combination approaches with lenalidomide demonstrate acceptable tolerability and antitumor activity in relapsed/refractory diffuse large B-cell lymphoma, with overall response rates approaching 58% at optimal dosing.

Beyond hematologic malignancies, BTK targeting addresses diverse pathologic roles. BTK degradation by NX-5948 provides selective antithrombotic benefits by impairing platelet activation through the GPVI pathway while preserving thrombin-mediated hemostasis, establishing a therapeutic window distinct from existing antiplatelet agents. In neuroinflammatory contexts, zinc supplementation inhibits BTK phosphorylation in macrophages to mitigate Japanese encephalitis virus-induced brain inflammation, and BTK has been identified as a common biomarker of both Alzheimer's disease and postoperative delirium, suggesting a shared immunopathologic axis. BTK activity in neutrophils is essential for initiating and maintaining skin inflammation in pemphigoid diseases, and selective BTK inhibition shows efficacy in rheumatoid arthritis through suppression of B-cell activation and autoantibody production.

The emergence of BTK resistance mechanisms shapes current drug development priorities. Four prevalent catalytic domain mutations—A428D, T474I, C481S, and L528W—significantly reduce binding free energies of non-covalent inhibitors and disrupt critical inhibitor-protein interactions, explaining clinical relapse in chronic lymphocytic leukemia. BTK degraders introduce a mechanistically distinct modality that may overcome certain covalent inhibitor resistance patterns, though downstream signaling escape and disease-dependent adaptive programs continue to present evolving challenges. Ongoing optimization of BTK-directed agents encompasses both structure-guided discovery of novel chemotypes and pharmacokinetic modeling to establish appropriate dosing across patient populations, reflecting sustained commitment to expanding BTK-targeting efficacy beyond current clinical limitations.

Key Publications

• NEWJun Selective degradation of platelet BTK by PROTAC NX-5948 provides antithrombotic benefits without affecting haemostasis. (Blood advances, 2026, PMID 42379226): "BTK acts as a key signalling switch that drives platelet activation during thrombosis but is largely dispensable for routine haemostasis."
• NEWJun BTK Degraders in Lymphoid Malignancies: New Modality, New Resistance Rules?. (Blood cancer discovery, 2026, PMID 42360198): "After more than a decade of clinical experience with BTK inhibitors, resistance to BTK targeting has become a moving target, shaped by drug-specific BTK mutations, downstream signaling escape, and disease-dependent adaptive programs."
• NEWJun Zinc Inhibits BTK Phosphorylation in Macrophages to Ameliorate Encephalitis in Neurotropic Virus-Infected Mice. (FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026, PMID 42340066): "Besides, zinc inhibited the phosphorylation of Bruton's tyrosine kinase (BTK) and NF-κB p65 in macrophages, thereby effectively curbing excessive neuroinflammation and alleviating JEV-induced neuronal damage in the murine brain."
• NEWJun Real-World Outcomes Among Medicare Beneficiaries Treated with Bruton Tyrosine Kinase Inhibitors for Treatment-Naïve CLL. (Oncology and therapy, 2026, PMID 42329588): "There is a dearth of head-to-head studies comparing covalent Bruton tyrosine kinase (cBTK) inhibitors in adults with chronic lymphocytic leukemia (CLL)."
• NEWJun BTKi orelabrutinib improved the outcome of newly-diagnosed PCNS-LBCL by alleviating MyD88L265P-induced PIM1 stability. (Journal of hematology & oncology, 2026, PMID 42310786): "In this study, we found that in the presence of MyD88L265P context, B-cell receptor downstream bruton's tyrosine kinase (BTK) was significantly overexpressed, which subsequently enhanced the stability of PIM1 oncoprotein."
• NEWJun Novel BTK inhibitors and degraders for relapsed/refractory CLL/SLL: latest updates from ASH 2025 annual meeting. (Journal of hematology & oncology, 2026, PMID 42252468): "Although covalent and non-covalent Bruton tyrosine kinase inhibitors (BTKi) have extended clinical benefit to relapsed/refractory (R/R) and BTKi-resistant chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), there remains an unmet need for additional B-cell receptor (BCR) pathway targeted therapies for highly refractory disease."
• May Common biomarkers of Alzheimer disease and postoperative delirium. (Medicine, 2026, PMID 42216384): "Five hub genes emerged as potential diagnostic biomarkers for both diseases, Bruton tyrosine kinase (BTK), NCF2, CRH, FCGR3A, and SERPINA3."
• May Candidate MRI biomarkers for CD79B status in primary CNS lymphoma: an exploratory radiogenomic analysis of the UCSF-PCNSL cohort. (Journal of neuro-oncology, 2026, PMID 42213292): "...of potential relevance to Bruton tyrosine kinase (BTK) inhibitor stratification."
• May Efficacy and safety of branebrutinib (BMS-986195), an irreversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2a, randomised, double-blind, placebo-controlled study. (The Lancet. Rheumatology, 2026, PMID 42081904): "Branebrutinib, an oral, highly selective, and irreversible Bruton's tyrosine kinase inhibitor, is a potential candidate for rheumatoid arthritis treatment as Bruton's tyrosine kinase has a role in B-cell activation, autoantibody production, and proinflammatory cytokine release, all of which are implicated in rheumatoid arthritis disease activity and progression."
• May Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies. (CPT: pharmacometrics & systems pharmacology, 2026, PMID 42067967): "Nemtabrutinib is a Bruton's tyrosine kinase (BTK) inhibitor under clinical investigation in patients with hematologic malignancies, including chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL)."